prikaz prve stranice dokumenta Infekcije u djece s akutnom limfatičnom leukemijom
  Download
PDF 1.45 MB
master's thesis
Infekcije u djece s akutnom limfatičnom leukemijom
2022. urn:nbn:hr:184:158353
Vranešević, Klara
University of Rijeka
Faculty of Medicine
Department of Pediatrics

Cite this document

Vranešević, K. (2022). Infekcije u djece s akutnom limfatičnom leukemijom (Master's thesis). Rijeka: University of Rijeka, Faculty of Medicine. Retrieved from https://urn.nsk.hr/urn:nbn:hr:184:158353

Vranešević, Klara. "Infekcije u djece s akutnom limfatičnom leukemijom." Master's thesis, University of Rijeka, Faculty of Medicine, 2022. https://urn.nsk.hr/urn:nbn:hr:184:158353

Vranešević, Klara. "Infekcije u djece s akutnom limfatičnom leukemijom." Master's thesis, University of Rijeka, Faculty of Medicine, 2022. https://urn.nsk.hr/urn:nbn:hr:184:158353

Vranešević, K. (2022). 'Infekcije u djece s akutnom limfatičnom leukemijom', Master's thesis, University of Rijeka, Faculty of Medicine, accessed 08 April 2025, https://urn.nsk.hr/urn:nbn:hr:184:158353

Vranešević K. Infekcije u djece s akutnom limfatičnom leukemijom [Master's thesis]. Rijeka: University of Rijeka, Faculty of Medicine; 2022 [cited 2025 April 08] Available at: https://urn.nsk.hr/urn:nbn:hr:184:158353

K. Vranešević, "Infekcije u djece s akutnom limfatičnom leukemijom", Master's thesis, University of Rijeka, Faculty of Medicine, Rijeka, 2022. Available at: https://urn.nsk.hr/urn:nbn:hr:184:158353

Please login to the repository to save this object to your list.
Metadata
TitleInfekcije u djece s akutnom limfatičnom leukemijom
Title (english)Infections in children with acute lymphoblastic leukemia
AuthorKlara Vranešević
MentorJelena Roganović (mentor)
Committee memberSrđan Banac (predsjednik povjerenstva)
Committee memberIgor Prpić (član povjerenstva)
Committee memberSrećko Severinski (član povjerenstva)
GranterUniversity of Rijeka
Faculty of Medicine
(Department of Pediatrics)
Rijeka
Defense date and country2022-07-15, Croatia
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Pediatrics
Abstract
Provedeno je retrospektivno istraživanje infektivnih komplikacija u pacijenata oboljelih od akutne limfatične leukemije (ALL), liječenih prema ALL IC-BFM protokolu od 2016. do 2020. godine na Zavodu za hematologiju, onkologiju i kliničku genetiku Kliničkog bolničkog centra Rijeka. U istraživanje je bilo uključeno 23 djece (16 dječaka i 7 djevojčica) s ALL-om, 20 intermedijarnog rizika i 3 visokog rizika. Prosječna dob bila je 5,9 godina (raspon 1,2 – 12,2 godine). Svi su pacijenti... More imali ugrađen centralni venski kateter i svi su primali oralni trimetoprim/sulfametoksazol za profilaksu Pneumocystis jiroveci pneumonije. Obrađene su 104 infektivne epizode (IE): 1 pacijent je imao 1 IE, 3 pacijenta 2 IE, a 19 pacijenata je imalo ≥ 3 IE (prosječno 4,5 IE po pacijentu). IE su najčešće bile dokumentirane tijekom faze rane intenzifikacije. Neutropenija je bila prisutna u 48 IE (46,15%), s trajanjem duljim od 7 dana u 28 epizoda (58,33%). Respiratorni trakt je bio najčešće sijelo infekcije (48,08%), a slijedi ga gastrointestinalni trakt (8,65%). Identificirano je bilo 49 izolata bakterija (47,12%), 4 virusna (3,85%), 4 gljivična (3,85%), 10 miješanih (9,6%), a u 37 IE (35,6%) patogen nije bio identificiran. Glavni uzročnici bakterijemije bili su koagulaza-negativni stafilokoki. Najčešća empirijska terapija bili su cefalosporini treće i četvrte generacije, a slijedi piperacilin/tazobaktam. Modifikacija prve linije antimikrobne terapije bila je potrebna u 58 IE (56,9%). Granulocitni čimbenik rasta bio je primijenjen u 56 IE (53,85%), a intravenski imunoglobulini u 65 IE (62,5%). Jedan pacijent je zahtijevao prijem na jedinicu intenzivnog liječenja. Nije zabilježena smrtnost povezana s infekcijom. Less
Abstract (english)
This is a retrospective study of infectious complications in patients with acute lymphoblastic leukemia (ALL) treated in ALL IC-BFM protocol from 2016 to 2020 at the Division of Hematology and Oncology, Department of Pediatrics, Clinical Hospital Centre Rijeka. Twenty-three children (16 boys and 7 girls) with ALL (20 intermediate risk and 3 high risk-ALL) were included in the study. The median age was 5.9 years (range 1.2 – 12.2 years). All patients had implanted central venous... More catheters and were receiving oral trimethoprim/sulfametoxazole for Pneumocystis jiroveci pneumonia prophylaxis. We verified 104 infectious episodes (IE): 1 patient had 1 IE, 3 patients had 2 IE, and 19 patients had ≥3 IE (average 4.5 IE/patient). IE were mostly observed during the early intensification phase. Neutropenia was present in 48 IE (46.15%), with duration longer than 7 days in 28 episodes (58.33%). Respiratory tract was the most common site of infection (48.08%), followed by gastrointestinal tract (8.65%). There were 49 bacterial isolates (47.12%), 4 viral (3.85%), 4 fungal (3.85%), 10 mixed (9.6%), and in 37 IE (35.6%) associated pathogen was not identified. The main cause of bacteriemia were coagulase-negative staphylococci. The most common empiric therapy was third- and fourth-generation cephalosporins, followed by piperacillin/tazobactam. Modification of first-line antimicrobial therapy was required in 58 IE (56.9%). Granulocyte colony stimulating factor was administered in 56 IE (53.85%), and intravenous immunoglobulins in 65 IE (62.5%). One patient required admission to the intensive care unit. No infection-related death was observed. Less
Keywords
Keywords (english)
Languagecroatian
URN:NBNurn:nbn:hr:184:158353
Study programmeTitle: Medicine
Study programme type: university
Study level: integrated undergraduate and graduate
Academic / professional title: doktor/doktorica medicine (doktor/doktorica medicine)
Type of resourceText
File originBorn digital
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2022-07-11 19:07:03
accessibility

closeAccessibilityrefresh

If you wish to permanently save changes, click on Save, if not - your settings will be reset when you restart the browser.